Jonathan W Goldman

Trials

Studies that name Jonathan W Goldman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:25 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07323641 · Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

  Jonsson Comprehensive Cancer Center · recruiting · Lung Non-Small Cell Carcinoma · principal investigator
• Ph2
  NCT06980077 · Ivonescimab for the Treatment of Thymic Cancer

  Jonsson Comprehensive Cancer Center · recruiting · Thymus Carcinoma · principal investigator
• Ph1/Ph2
  NCT04285671 · Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

  Jonsson Comprehensive Cancer Center · active not recruiting · Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 · principal investigator
• Ph1/Ph2
  NCT03830918 · Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

  Jonsson Comprehensive Cancer Center · active not recruiting · Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 15:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.